Call for studies by the DCCV on CRP apheresis in Crohn's disease and ulcerative colitis  

28.6.2023

The German Crohn's Disease / Ulcerative Colitis Association and the Federal Association for Chronic Inflammatory Diseases of the Digestive Tract (DCCV) e.V. are looking for study participants for the clinical study on the selective depletion of the C-reactive protein by means of therapeutic apheresis (CRP apheresis) in Crohn's disease and ulcerative colitis ( CAMCRO1).

With our help, the Havelhöhe Hospital in Berlin is conducting a clinical trial on reducing the plasma concentration of C-reactive protein (CRP) using therapeutic apheresis (CRP apheresis) in patients with Crohn's disease and ulcerative colitis. The aim of the study is to reduce the gastrointestinal inflammatory process by lowering the CRP level during an acute flare-up.

You can access the call for studies here.